The Epidemiology of Human Chondrogenic Progenitor Cells

描述(由申请人提供)：该项目旨在通过确定选择和优化软骨结缔组织前体细胞(CTP-Cs)可用来源的策略和原则来推动软骨组织工程领域的发展。它还将为组织工程界提供一种严格和标准化的量化方法，用于客观评估和比较细胞来源和加工方案。软骨组织的成功修复或再生需要CTP-Cs的来源，即能够 软骨细胞分化。软骨修复策略必须依赖于几个细胞来源中的一个 战略。具有成软骨潜能的CTPs存在于软骨、骨髓、骨膜、肌肉、脂肪等组织中。其中一些组织来源已经或正在被利用，为软骨修复和再生程序提供细胞。尽管关节软骨组织显示出很小的内在修复能力，但在正常和 病变软骨组织在体外可以被诱导增殖和分化，表现为软骨细胞表型。这种软骨来源的CTP-Cs已经成为几种治疗策略的核心，这些治疗策略基于将新鲜分离的软骨组织或培养扩增的细胞移植到软骨缺损中。到目前为止，细胞来源的决定和细胞加工或制造战略通常不是基于对可用细胞来源的浓度、流行率或生物潜力的定量分析。该计划致力于改善临床实践的三个机会：1)确定成人膝关节内和周围(关节软骨、脂肪垫、滑膜、骨膜、软骨下骨和骨髓)中软骨源性结缔组织前体细胞(CTP-Cs)的浓度、流行率和生物学潜力。2)明确软骨组织健康与软骨中CTP-Cs的浓度、发生率和生物学潜力的关系。3)验证CTP-C来源之间的体外表现差异预测体内表现差异的假设。

DESCRIPTION (provided by applicant): This program seeks to advance the field of Cartilage Tissue Engineering by defining strategies and principles for selecting and optimizing available sources of chondrogenic connective tissue progenitors (CTP- Cs). It will also provide the tissue engineering community with a rigorous and standardized quantitative methodology for objective evaluation and comparison of cell sourcing and processing options. Successful repair or regeneration of cartilage tissue requires a source of CTP-Cs, i.e. native cells that are capable of chondrogenic differentiation. Cartilage repair strategies must rely on one of several cell sourcing strategies. CTPs with chondrogenic potential reside in cartilage, as well as bone marrow, periosteum, muscle, fat and other tissues. Several of these tissue sources have already been or are being exploited to provide cells for cartilage repair and regeneration procedures. Although articular cartilage tissue shows little intrinsic capacity to repair, some cells in both normal and diseased cartilage tissue can be induced to proliferate and differentiate to express a chondrocytic phenotype in vitro. Such cartilage-derived CTP-Cs have become central to several treatment strategies based on transplantation of freshly isolated cartilage tissue or culture-expanded cells into a cartilage defect. To date, cell sourcing decisions and cell processing or fabrication strategies have generally not been based on quantitative assays of the concentration, prevalence or biological potential of the available cell sources. This program addresses three opportunities to improve clinical practices: 1) Define the concentration, prevalence and biological potential of chondrogenic connective tissue progenitors (CTP-Cs) in and around the adult human knee (articular cartilage, fat pad, synovium, periosteum, subchondral bone and marrow). 2) Define the relationship between cartilage tissue health and the concentration, prevalence and biological potential of CTP- Cs in human cartilage. 3) Test the hypothesis that differences in in vitro performance between CTP-C sources predict differences in in vivo performance.